ASCO 2026: AI Challenges a Breast Cancer Standard - Takeaways - MDSpire
Advertisement
ASCO 2026: AI Challenges a Breast Cancer Standard
New data suggest AI-based analysis of pathology slides may provide additional prognostic information, particularly for patients in the intermediate-risk category
The Artera breast model is an FDA-cleared AI tool that integrates digital pathology and clinical variables for breast cancer risk stratification.
2
In a study of over 300 early-stage breast cancer patients, the Artera AI tool outperformed the 21-gene recurrence score in prognostic value.
3
Patients with concordantly low scores from both Artera and Oncotype had no distant recurrences at 10 years, indicating strong prognostic accuracy.
4
Discordant scores showed a significant difference in 10-year distant metastasis rates, with 20% recurrence in patients with Oncotype low and Artera high.
5
The study suggests that the Artera AI tool provides additional prognostic information beyond traditional recurrence score categories.
